MASI
Masimo Corporation134.52
-2.88-2.1%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.23BP/E (TTM)
-Basic EPS (TTM)
-4.55Dividend Yield
0%Recent Filings
10-K
FY2025 results
Masimo delivered FY2025 revenue of $1.53B, up 9.4% y/y, driven by consumables strength and an extra selling week, with Q4 momentum from record customer conversions despite installation backlogs. Gross margins expanded to 61.9% from 56.9%, fueled by manufacturing efficiencies in Malaysia and favorable mix, while SG&A and R&D fell sharply post-realignment. Operating income soared to $310M (20.3% margin) versus $63M prior year. Q4 accelerated growth; margins progressed strongly. Strong liquidity with $152M cash and $468M revolver availability. Proposed Danaher merger expected H2 2026. Regulatory delays could stall quarterly momentum.
8-K
Danaher buys Masimo at $180/share
Masimo inked a merger deal with Danaher on February 16, 2026, for $180 per share in cash, totaling $9.9 billion. Danaher's sub will merge into Masimo, which survives as a standalone diagnostics unit while retaining autonomy. Politan Capital, owning 4.6 million shares, pledged support. Stockholder vote and antitrust nods required; $305M breakup fee looms if Masimo bolts.
8-K
Masimo's strong prelim 2025 results
Masimo released preliminary Q4 2025 results on January 12, 2026, showing revenue of ~$411M (12% reported growth) and non-GAAP EPS over $1.54 despite tariffs. Full-year revenue hit ~$1,523M (9% growth), with EPS exceeding $5.55 at guidance high end. Shipments reached 69K units quarterly, 270K annually. Full results due February 26; figures preliminary pending audit.
8-K
Masimo sets 7-10% CAGR targets
Masimo hosted its 2025 Investor Day on December 3, unveiling a strategic roadmap targeting 7%-10% revenue CAGR through 2028, ~30% operating margin, $8.00 adjusted EPS, and ~$1B cumulative operating cash flow from 2026-2028. Management reaffirmed FY2025 non-GAAP guidance of $1,510-$1,530M revenue and $5.40-$5.55 EPS, emphasizing pulse oximetry share gains, advanced monitoring expansion, and new product launches. Growth hinges on execution amid tariffs.
8-K
Masimo refinances $1B credit facility
Masimo refinanced its credit agreement on December 1, 2025, terminating the prior facility with Citibank and entering a new $250M term loan and $750M revolver from Bank of America-led lenders, maturing December 1, 2030. Rates tie to net leverage, starting at Term SOFR plus 1.000%-1.750%, with no SOFR adjustment—unlike before. New liquidity. Covenants mirror the old deal.
BRKR
Bruker Corporation
44.96-0.71
BSX
Boston Scientific Corporation
92.95+0.76
ENOV
Enovis Corporation
26.07-0.47
HAE
Haemonetics Corporation
81.11+0.71
IRIX
IRIDEX Corporation
1.00+0.02
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
MDT
Medtronic plc.
97.72-0.85
NMTC
NeuroOne Medical Technologies C
0.71+0.05
RMD
ResMed Inc.
247.34-5.73